1. Academic Validation
  2. AXL kinase inhibition promotes cytosolic DNA sensor cGAS activity and sensitizes poorly immunogenic tumors to chemo-immunotherapy

AXL kinase inhibition promotes cytosolic DNA sensor cGAS activity and sensitizes poorly immunogenic tumors to chemo-immunotherapy

  • Mol Cancer Ther. 2025 Nov 20. doi: 10.1158/1535-7163.MCT-24-0440.
Sushil Dhakal 1 Muntequa I Siraji 1 Sturla M Grøndal 1 Gard N Skarsten 1 Emmanuel E Moutoussamy 1 Gro Gausdal 2 James B Lorens 1 Sébastien Bougnaud 1
Affiliations

Affiliations

  • 1 University of Bergen, Bergen, Norway.
  • 2 BerGenBio ASA, Bergen, Norway.
Abstract

Axl is an important negative regulator of type I interferon (IFN) responses during viral infections. In the context of tumors, Axl is associated with driving tumor progression, spread, immune evasion, and therapy resistance. Axl regulation of tumor cell intrinsic IFN responses remains unexplored. We show that Axl suppresses tumor intrinsic IFN responses by inhibiting the cytosolic DNA sensor cGAS via an AKT-dependent pathway. Axl inhibition in combination with chemo-immunotherapy demonstrated potent anti-tumor effects in poorly immunogenic tumors that are refractory to immunotherapy. The inhibition of Axl correlated with increased cGAMP levels, activation of IFN, and enhanced infiltration of T cells and NK cells into the tumor microenvironment. These findings reveal a novel role for Axl in suppressing IFN within tumors and support Axl targeting as a promising strategy in conjunction with chemo-immunotherapy for treating therapy-resistant tumors.

Figures
Products